Stelara was first approved for psoriasis 10 years ago, and follow-up indications in psoriatic arthritis and Crohn’s disease have kept the drug growing at a healthy pace to reach more than $5 ...

linking the pathogenesis of Crohn’s disease with this inflammation pathway. The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...

The global market for ustekinumab, Stelara's active ingredient ... options to patients diagnosed with ulcerative colitis, Crohn's disease, psoriasis, and psoriatic arthritis,” said Celltrion ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Stelara (ustekinumab) was launched almost 15 years ago as a treatment for psoriasis and in the interim has picked up additional indications in psoriatic arthritis, Crohn’s disease, and ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active Crohn's disease, drugmaker Eli Lilly announced; the first-in-class interleukin-23 ...

Vigorous protection of Stelara’s position in the immunology ... colitis and an expected approval of the therapy for Crohn’s disease. Duato also mentioned that the company views the future ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

Johnson & Johnson (JNJ) stock fell on Wednesday even as the healthcare giant posted better-than-expected financials for Q4 ...